Report Details:
15 Companies Covered
171 Pages
Global Liquid Biopsy market is expected to grow at a CAGR of 10.52% by 2035
Market Research Future (MRFR) has published a cooked research report on the “Global Liquid Biopsy Market” that contains information from 2019 to 2035. The Liquid Biopsy Market is estimated to register a CAGR of 10.52% during the forecast period of 2025 to 2035.
Market Highlights
The Global Liquid Biopsy Market is accounted for to register a CAGR of 10.52% during the forecast period and is estimated to reach USD 27.34 Billion by 2035 from USD 9.10 Billion in 2024.
The increasing prevalence of cancer, growing demand for non-invasive diagnostic methods, and rapid technological advancements are driving significant market growth. Liquid biopsies offer a revolutionary approach to cancer detection and monitoring, providing real-time insights into tumor genetics without the need for invasive tissue sampling. The growing emphasis on personalized medicine and early cancer detection further enhances the market’s potential.
The Cancer Diagnosis segment is projected to dominate the market, expected to reach USD 2.2 Billion in 2024, driven by the increasing demand for early and accurate cancer detection. North America leads regionally with a valuation of USD 2.5 Billion in 2024, owing to advanced healthcare infrastructure, high R&D spending, and early adoption of innovative diagnostic technologies.
Key companies are putting a lot of money into next-generation sequencing (NGS) and digital PCR technologies to make assays more sensitive and accurate. This will speed up market growth even more through 2035.
Segment Analysis
The Global Liquid Biopsy Market has been segmented based on Application, Sample Type, Technology, End Use, and Region.
By Application: Cancer Diagnosis, Treatment Monitoring, Recurrence Monitoring, Clinical Trials, and Research Applications.
The Cancer Diagnosis segment dominated the market in 2024 with a valuation of USD 2.2 Billion, followed by Treatment Monitoring at USD 1.3 Billion, as the need for precision oncology continues to rise.
By Sample Type: Blood, Urine, Saliva, Pleural Fluid, and Cerebrospinal Fluid.
Blood-based liquid biopsies are expected to remain the most widely used sample type due to their ease of collection and accuracy.
By Technology: Next-Generation Sequencing (NGS), Digital PCR, Microfluidics, Exosome Isolation, and Circulating Tumor Cells (CTCs).
NGS and Digital PCR are leading technologies, providing high sensitivity and specificity for detecting cancer biomarkers and guiding therapeutic decisions.
By End Use: Hospitals, Diagnostic Laboratories, Research Institutes, and Pharmaceutical Companies.
Hospitals and Diagnostic Laboratories hold the largest share due to increasing clinical adoption of liquid biopsy testing for real-time cancer management.
By Region: North America, Europe, Asia Pacific, South America, and the Middle East & Africa.
North America leads the global market, projected to reach USD 6.8 Billion by 2035, followed by Europe at USD 3.8 Billion and Asia Pacific at USD 3.3 Billion, supported by growing cancer burden and expanding diagnostic infrastructure.
Key Players
MRFR recognizes the following companies as the key players in the Global Liquid Biopsy Market —GRAIL, Natera, Foundation Medicine, Exact Sciences, Thermo Fisher Scientific, and Illumina.
These players are focusing on technological innovations, regulatory approvals, strategic collaborations, and product expansion to strengthen their market presence. For instance, GRAIL’s cutting-edge genomic sequencing technologies and Natera’s personalized tumor assays exemplify the growing shift toward precision diagnostics and patient-specific treatment strategies.
Key Findings of the Study
- The Global Liquid Biopsy Market is expected to reach USD 27.34 Billion by 2035, growing at a CAGR of 10.52% during 2025–2035.
- Cancer Diagnosis accounted for the largest market share in 2024.
- North America led the global market and is expected to continue its dominance through 2035.
- Next-Generation Sequencing (NGS) and Digital PCR technologies are driving innovation in cancer detection and treatment monitoring.
- Key players such as GRAIL, Natera, Foundation Medicine, Exact Sciences, Thermo Fisher Scientific, and Illumina are leading market advancements through R&D and strategic partnerships.
Related Reports
https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710